Hepatology. 2022 May 19. doi: 10.1002/hep.32578. Online ahead of print.
Nonalcoholic fatty liver disease and accelerated loss of skeletal
muscle mass: A longitudinal cohort study
Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon
Park, Juhee Cho , Geum-Youn
Gwak
Abstract
Background and aims: Whether subjects with NAFLD are at increased
risk of sarcopenia is not well established.
Approach and results: This is a cohort study of 52,815 men and
women of 20 years of age or older who underwent at least two health check-up
exams with bioelectrical impedance analysis and abdominal ultrasound imaging.
Bioelectrical impedance analysis was used to calculate appendicular skeletal
muscle mass (ASM). NAFLD was assessed by ultrasonography, and its severity
was assessed by the NAFLD fibrosis score (NFS). We estimated the 5-year
change in ASM comparing participants with and without NAFLD at baseline using
mixed linear models. The 5-year change in ASM in participants without and
with NAFLD was -225.2 g (95% CI -232.3, -218.0) and -281.3 g (95% CI -292.0,
-270.6), respectively (p < 0.001). In multivariable adjusted analysis, the
difference in 5-year change in ASM comparing participants with and without
NAFLD was -39.9 g (95% CI -53.1, -26.8). When participants with NAFLD were
further divided by NAFLD severity, ASM loss was much faster in participants
with NAFLD with intermediate to high NFS than in those with low NFS.
Conclusions: Participants with NAFLD were at increased
risk of sarcopenia, indicated by faster loss of skeletal muscle mass.
Patients with NAFLD may need screening and early intervention to mitigate
skeletal muscle mass loss.
|